On the recordFebruary 14, 2012
Our medical innovation system is in jeopardy. Investment in life science area is declining at an alarming rate because of the escalating cost, time and risk of developing new drugs and devices.
Source
congress.govEditor's note · Context
Pitts highlights concerns over declining investment in medical innovation due to regulatory issues.
Share
More from Joe Pitts
Sep 7, 2016
H.R. 3119, the Palliative Care and Hospice Education and Training Act, sponsored by Rep. Engel (NY) increases the number of permanent faculty in palliative care.
Sep 7, 2016
H.R. 1807, the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015, sponsored by Rep. Danny Davis (IL) and Rep. Michael Burgess (TX) reauthorizes a sickle cell disease demonstration program.
Jul 6, 2016
I applaud the cosponsors for working through the committee to address serious stakeholder concerns by taking a new approach in the draft we are discussing today.
Jul 11, 2016
One of our main challenges in addressing emergency and trauma care is leadership.
Other voices in this conversation
